{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:27:00Z","timestamp":1786591620983,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004737","name":"National Health Research Institutes","doi-asserted-by":"publisher","award":["CRD42023471362"],"award-info":[{"award-number":["CRD42023471362"]}],"id":[{"id":"10.13039\/501100004737","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","surveyophthalmol.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.survophthal.2024.12.006","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:53Z","timestamp":1734652853000},"page":"380-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Enhancing anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy: A meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Ting-Han","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Chen","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.survophthal.2024.12.006_bib1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2024.12.006_bib2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2024.12.006_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41433-021-01688-7","article-title":"Evolving treatment paradigms for PCV","volume":"36","author":"Fenner","year":"2022","journal-title":"Eye"},{"key":"10.1016\/j.survophthal.2024.12.006_bib4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib5","unstructured":"Higgins J P T T J , Chandler J, Cumpston M, Li T, Page M J, Welch V A (editors).: Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). 2023."},{"key":"10.1016\/j.survophthal.2024.12.006_bib6","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.survophthal.2010.03.004","article-title":"Polypoidal Choroidal Vasculopathy: A Review","volume":"55","author":"Imamura","year":"2010","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib7","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000354546","article-title":"Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy","volume":"231","author":"Kang","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2024.12.006_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2024.12.006_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/IAE.0b013e3182852446","article-title":"Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment","volume":"33","author":"Koh","year":"2013","journal-title":"RETINA"},{"key":"10.1016\/j.survophthal.2024.12.006_bib11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000354072","article-title":"Polypoidal choroidal vasculopathy exudation and hemorrhage: results of monthly ranibizumab therapy at one year","volume":"231","author":"Kokame","year":"2013","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2024.12.006_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12886-018-0801-7","article-title":"Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1\u2009+\u2009PRN regimen","volume":"18","author":"Lai","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial","volume":"136","author":"Lee","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1755-3768.2009.01841.x","article-title":"Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study","volume":"90","author":"Lim","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jamaophthalmol.2020.2443","article-title":"Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: The EVEREST II randomized clinical trial","volume":"138","author":"Lim","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.preteyeres.2013.09.003","article-title":"Photodynamic therapy for polypoidal choroidal vasculopathy","volume":"37","author":"Nowak-Sliwinska","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2024.12.006_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s10384-020-00805-5","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: 96-week outcomes in the Japanese subgroup of the PLANET study","volume":"65","author":"Ogura","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.survophthal.2024.12.006_bib19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/OPTH.S385827","article-title":"Polypoidal choroidal vasculopathy: an update on diagnosis and treatment","volume":"17","author":"Sen","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib20","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000518235","article-title":"Efficacy and safety of intravitreal aflibercept treat and extend for polypoidal choroidal vasculopathy in the atlantic study: a randomized clinical trial","volume":"245","author":"Silva","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2024.12.006_bib21","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00417-005-1139-4","article-title":"Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin","volume":"243","author":"Silva","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium\u2013derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/IAE.0b013e3181a3b7c5","article-title":"Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions","volume":"29","author":"Tsuchiya","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2024.12.006_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.survophthal.2024.12.006_bib25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajo.2019.02.027","article-title":"Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy: two-year results of the aflibercept in polypoidal choroidal vasculopathy study","volume":"204","author":"Wong","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0021-5155(03)00042-X","article-title":"A study of laser photocoagulation for polypoidal choroidal vasculopathy","volume":"47","author":"Yuzawa","year":"2003","journal-title":"Jpn J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2024.12.006_bib27","first-page":"1280","article-title":"Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a meta-analysis","volume":"10","author":"Han","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.survophthal.2024.12.006_bib28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00417-020-04977-1","article-title":"The polyp regression rate and treatment prognosis of different interventions for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"259","author":"Zhao","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625724001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:46:15Z","timestamp":1741099575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625724001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0039625724001577"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.12.006","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2024.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}